Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher tous les synonymes
Sélectionnez vos espèces d'intérêt
Relatively high levels of KLK13 expression in ESCC were associated with cell proliferation and correlated with tumor progression, advanced cancer stage, and poor prognosis
Decreased KLK13 mRNA levels correlate with poor survival in esophageal squamous cell carcinoma patients.
There was no significant association of KLK13 and KLK14 mRNA expression with the clinical factors ascitic fluid volume or residual tumor mass. In univariate Cox regression analysis, elevated KLK13 mRNA levels were significantly linked with shorter progression-free (PFS; hazard ratio [HR] = 1.97, P = 0.020) and overall survival (OS; HR = 1.81, P = 0.041).
This first clinical study of KLK13 in bladder cancer reveals its deregulated expression in bladder tumors and highlights KLK13 as a promising marker for improving TaT1 patients' prognosis following treatment.
Our results suggest that KLK13 mRNA expression constitutes a novel biomarker for the prediction of overall survival in nonsmall cell lung cancer and that its quantitative assessment in tumor tissues can aid in treatment decision making.
KLK13 may play an important role in regulating cellular migration and invasiveness, making the loss of KLK13 a potential biomarker for early detection of lymph node metastasis in oral squamous cell carcinomas.
The aim of this study was to monitor serum levels of two microRNAs (miR-21 and miR-141) and three kallikreins (hK3/PSA, hK11, and hK13) before and 1, 5, and 30 days after radical prostatectomy.
Data indicate that five out of 9 SNPs in the KLK13 gene were associated with prostate cancer risk and/or aggressiveness.
High KLK13 expression is associated with drug response in gastric cancer.
Results indicate that KLK13 may play a role in the defense of the upper digestive apparatus and in male reproductive organs.
Serine protease of Kazal-type (SPINK6) expressed in normal human skin is a potent natural inhibitor of Kallikrein-related peptidases, KLK12 and KLK13.
these results reveal the enhancing effects of KLK13 on tumor cell invasion and migration, and that it may serve as a diagnostic/prognostic marker and a potential therapeutic target for lung cancer.
This is the first study disclosing the possible clinical utility of KLK13 as a new tumor biomarker capable of predicting a favorable outcome for gastric cancer patients.
KLK13 expression is an independent favorable prognostic marker for breast carcinoma
kallikrein 13 is expressed in the nonmalignant and malignant prostate, with cancer tissues demonstrating slightly lower expression
hK13 interacts and forms complexes with serum protease inhibitors, including alpha2-macroglobulin, alpha1-antichymotrypsin and alpha2-antiplasmin
Human kallikrein13 may play a role in tissue remodeling and/or tumor invasion and metastasis.
hK13 is expressed in several common salivary gland tumors
non-small-cell lung cancer patients with high KLK13 expression at the mRNA or protein level had lower overall survival
Combination of KLK2, 3, 13, and 14 and KLK1, 2, 5, 6, 7, 8, 10, 13, and 14 showed very strong discriminatory potential for semen liquefaction and viscosity, respectively.
kallikrein mK13 is a plausible candidate for the processing enzyme for pro-IL-1beta in the submandibular gland of mice
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Expression of this gene is regulated by steroid hormones and may be useful as a marker for breast cancer. An additional transcript variant has been identified, but its full length sequence has not been determined.
, kallikrein-like gene 4
, kallikrein-like protein 4